Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations

Kassouf, Wassim; Traboulsi, Samer L.; Schmitz‐Dräger, Bernd J.; Palou, Joan; Witjes, J. Alfred; Rhijn, Bas W.G. van; Grossman, H. Barton; Kiemeney, Lambertus A.; Goebell, Peter J.; Kamat, Ashish M.

doi:10.1016/j.urolonc.2016.05.028

Cited by 65 publications

(46 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, 5‐year tumour progression is observed in up to 45% of cases, especially in patients with high‐risk NMIBC which has the highest potential for tumour progression . These follow‐up data reflect the fact that NMIBC incorporates a wide and heterogeneous spectrum of tumours with a pleotropic molecular landscape, resulting in different prognoses and behaviours . This highlights the importance of comprehensive, standardized and risk‐adapted follow‐up protocols for patients with NMIBC, including regular cystoscopies and cytologies, as well as regular upper urinary tract imaging (for high‐risk tumours) as suggested by the European Association of Urology (EAU) guidelines .…”

Section: Introductionmentioning

confidence: 92%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

ObjectivesTo evaluate the diagnostic accuracy of the Xpert Bladder Cancer (BC) Monitor, compared with cystoscopy and cytology in the oncological follow-up of non-muscle-invasive bladder cancer (NMIBC). Material and MethodsA total of 140 patients with a history of NMIBC undergoing routine surveillance at our institution were enrolled prospectively in this study (ISRCTN study registry number 37210907). Urine cytology was evaluated according to the Paris classification system. In addition, urinary specimens were analysed using the Xpert BC Monitor, which measures five target mRNAs (ABL1, CRH, IGF2, UPK1B, ANXA10) using real-time PCR. Descriptive analysis, diagnostic accuracy including sensitivity, specificity, positive (PPV) and negative predictive value (NPV), receiver-operating characteristic curve, and area under the curve (AUC) were calculated. ResultsThe overall sensitivity (0. ConclusionIn this study, we report for the first time that the Xpert BC Monitor, a new mRNA-based urine test, outperforms cytology with regard to sensitivity and NPV, even in low-grade and pTa tumours, with no reduction of specificity.

show abstract

Section: Introductionmentioning

confidence: 92%

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Overall, BTA stat, ImmunoCyt, and Urovision present higher sensitivity when used as diagnosis and follow-up tools in comparison with urinary cytology but present a lower specificity. Due to their low sensitivity in the detection of low-grade tumors, it is suggested that these biomarkers might be more useful in the follow-up of high-risk tumors [55].…”

Section: Immunocyt/ucyt+mentioning

confidence: 99%

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

et al. 2020

View full text Add to dashboard Cite

Bladder cancer (BC) ranks as the sixth most prevalent cancer in the world, with a steady rise in its incidence and prevalence, and is accompanied by a high morbidity and mortality. BC is a complex disease with several molecular and pathological pathways, thus reflecting different behaviors depending on the clinical staging of the tumor and molecular type. Diagnosis and monitoring of BC is mainly performed by invasive tests, namely periodic cystoscopies; this procedure, although a reliable method, is highly uncomfortable for the patient and it is not exempt of comorbidities. Currently, there is no formal indication for the use of molecular biomarkers in clinical practice, even though there are several tests available. There is an imperative need for a clinical non-invasive testing for early detection, disease monitoring, and treatment response in BC. In this review, we aim to assess and compare different tests based on molecular biomarkers and evaluate their potential role as new molecules for bladder cancer diagnosis, follow-up, and treatment response monitoring.

show abstract

“…This high rate of recurrence requires that patients are submitted to an intensive follow-up program. Major guidelines from European Association of Urology (EAU) and Canadian Urological Association (CUA) recommend cystoscopy and urinary cytology every 3 months in the first 2 years, semi-annually during the subsequent 3 years and annually thereafter [9].…”

Section: Introductionmentioning

confidence: 99%

Uromonitor^®as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer

Sampaio

Batısta

Peralta

et al. 2018

Preprint

View full text Add to dashboard Cite

Bladder cancer is the most frequent malignancy of the urinary system and is ranked the seventh most diagnosed cancer in men worldwide. About 70-75% of all newly diagnosed patients with bladder cancer will present disease confined to the mucosa or submucosa, the non-muscle invasive bladder cancer (NMIBC) subtype. Of those, approximately 70% will recur after transurethral resection (TUR). Due to this high rate of recurrence, patients are submitted to an intensive follow-up program that should be maintained throughout many years, or even throughout life, resulting in an expensive follow-up, with cystoscopy being the most cost-effective procedure for NMIBC screening. Currently, the gold standard procedure for detection and follow-up of NMIBC is based on the association of cystoscopy and urine cytology. As cystoscopy is a very invasive approach, over the years, many different non-invasive (both in serum and urine samples) assays have been developed in order to search genetic and protein alterations related to the development, progression and recurrence of bladder cancer. TERT promoter mutations and FGFR3 hotspot mutations are the most frequent somatic alterations in bladder cancer and constitute the most reliable biomarkers for bladder cancer. Based on these findings, an ultra-sensitive assay called Uromonitor ® was developed that corresponds to a urinebased assay capable of detecting trace amounts of the two most common alterations in NMIBC, TERT promoter and FGFR3 mutation, in urine samples. The Uromonitor ® test was performed in a cohort of 72 patients, firstly diagnosed with bladder cancer and under surveillance for NMIBC, to access its sensitivity and specificity in the detection of NMIBC recurrence. Uromonitor ® was shown to be highly sensitive and specific in detecting recurrence of bladder cancer in patients under surveillance of non-muscle invasive bladder cancer.

show abstract

Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations

Cited by 65 publications

References 60 publications

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

Uromonitor^®as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer

Contact Info

Product

Resources

About

Follow-up in non–muscle-invasive bladder cancer—International Bladder Cancer Network recommendations

Cited by 65 publications

References 60 publications

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

Increased accuracy of a novel mRNA‐based urine test for bladder cancer surveillance

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review

Uromonitor®as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer

Contact Info

Product

Resources

About

Uromonitor^®as a novel sensitive and specific urine-based test for recurrence surveillance of patients with non-muscle invasive bladder cancer